Article
Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased dihydropyrimidine dehydrogenase enzyme activity.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners - 1 Jan 2023
Ockeloen Charlotte W, Raaijmakers Aron, Hijmans-van der Vegt Manon, Bierau Jörgen, de Vos-Geelen Judith, Willemsen Annelieke Ecab, van den Bosch Bianca Jc, Coenen Marieke Jh
Abstract excerpt
OBJECTIVE: To investigate if dihydropyrimidine dehydrogenase phenotyping has added value when combined with DPYD genotyping in predicting fluoropyrimidine-related toxicity. METHODS: Retrospective cohort study in which treatment and toxicity data were collected of 228 patients genotyped for four DPYD variants and phenotyped using an ex vivo peripheral blood mononuclear cell assay. RESULTS: Severe toxicity occurred...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.